Sirakova V, Penkov N, Kaponov Kh, Dimitrov G
Vutr Boles. 1986;25(2):32-6.
Obsilazin was established to have a good to moderate hypotensive effect in 75% of the treated 36 patients with moderate and severe hypertension under the condition of a 6-month open clinical experiment, not changing the heart rate. The adverse effects are often 69.4%), usually transitory but in 11.1% they proved to be the cause for discontinuation of the treatment.
在一项为期6个月的开放临床试验中,对36例中重度高血压患者进行治疗,结果显示奥昔拉嗪对75%的患者有良好至中等程度的降压作用,且不改变心率。不良反应发生率通常为69.4%,多为短暂性,但有11.1%的不良反应被证明是导致停药的原因。